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INTRODUCTION
Melanoma is the most aggressive of common skin cancers 
because of its tendency to metastasize. Its incidence is rapidly 
increasing, especially among Caucasian populations. Melanoma 
is the second most diagnosed cancer among patients younger 
than 30 years of age,1 and the 3-year survival rate for patients 
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Purpose: CDKN2A is the main high-risk melanoma-susceptibility 
gene, but it has been poorly assessed in Latin America. We sought 
to analyze CDKN2A and MC1R in patients from Latin America with 
familial and sporadic multiple primary melanoma (SMP) and com-
pare the data with those for patients from Spain to establish bases for 
melanoma genetic counseling in Latin America.
Methods: CDKN2A and MC1R were sequenced in 186 Latin 
American patients from Argentina, Brazil, Chile, Mexico, and Uru-
guay, and in 904 Spanish patients. Clinical and phenotypic data 
were obtained.
Results: Overall, 24 and 14% of melanoma-prone families in 
Latin America and Spain, respectively, had mutations in CDKN2A. 
Latin American families had CDKN2A mutations more frequently 
(P = 0.014) than Spanish ones. Of patients with SMP, 10% of those 
from Latin America and 8.5% of those from Spain had mutations in 
CDKN2A (P = 0.623). The most recurrent CDKN2A mutations were 
c.-34G>T and p.G101W. Latin American patients had fairer hair 
(P = 0.016) and skin (P < 0.001) and a higher prevalence of MC1R 
variants (P = 0.003) compared with Spanish patients.
Conclusion: The inclusion criteria for genetic counseling of mela-
noma in Latin America may be the same criteria used in Spain, as 
suggested in areas with low to medium incidence, SMP with at least 
two melanomas, or families with at least two cases among first- or 
second-degree relatives.
Genet Med advance online publication 17 December 2015
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with metastases is around 15%.2 Identification of individuals at 
high risk of developing melanoma is necessary since an early 
diagnosis improves the disease prognosis.3
Melanoma is caused by the interaction of environmental, 
phenotypic, and genetic factors. The main environmental risk 
factor for melanoma is sun exposure.4 Individuals with fair 
skin, red hair, and/or a high nevi count have an increased risk of 
developing melanoma.5 To date, CDKN2A, which encodes the 
tumor suppressor proteins p16INK4A and p14ARF, is the major 
high-risk gene involved in melanoma susceptibility.6 CDKN2A 
has been widely studied in melanoma patients from the United 
States, Europe, and Australia.6 The frequency of germline 
mutations in CDKN2A varies across populations (5–72%) and 
depends on the selection criteria used.6,7 Haplotype analysis 
indicates a founder effect for most of the recurrent mutations 
detected.8 Identification of the prevalence of CDKN2A muta-
tions in patients at high risk for melanoma and the correla-
tion of these mutations with clinical data has been crucial for 
establishing genetic counseling for melanoma. Melanoma risk 
may also be modulated by common genetic variants acting as 
low- to medium-penetrance variants.9 MC1R plays a key role 
in pigmentation and is responsible for phenotypic character-
istics such as hair and skin color and the capacity of response 
to ultraviolet radiation.10 Several MC1R variants are associated 
with a moderately increased melanoma risk and also modulate 
the effect of CDKN2A mutations in carriers.11
Genetic counseling and specific dermatological follow-up 
may be offered to patients at high risk for melanoma.12 In coun-
tries with a low to medium incidence of melanoma, genetic 
counseling is offered to patients with two primary melano-
mas and/or to families with two melanoma cases and/or one 
pancreatic adenocarcinoma and one melanoma in first- or 
second-degree relatives (the “rule of two”). In countries with 
a moderate to high incidence of melanoma, however, genetic 
counseling is offered to patients with three primary melanomas 
and to families with three cases of melanoma or pancreatic can-
cer in first- or second-degree relatives (the “rule of three”).13 It 
has been demonstrated that melanoma genetic counseling has 
a positive impact on the improvement of total body skin exami-
nation and self-examination of the skin in unaffected individu-
als carrying germline mutations after test reporting, whereas 
affected carriers maintain high levels of screening adherence.14 
Furthermore, after melanoma genetic counseling, unaffected 
members of high-risk melanoma families report improvements 
in daily routine sun protection, showing that genetic counseling 
may motivate sustained improvements in prevention behav-
iors.15 Thus it is very important for both melanoma patients and 
unaffected individuals from the family to be included in genetic 
counseling programs.
Few studies have assessed the prevalence of CDKN2A muta-
tions or MC1R variants and phenotypic characteristics in 
patients at high risk for melanoma from Latin American coun-
tries. CDKN2A mutations have been identified in 13.6% of 
melanoma-prone families from São Paulo, Brazil,16 whereas one 
study reported no mutations in Porto Alegre,17 and in a different 
cohort the mutation frequency was 7%.18 In melanoma-prone 
families from Uruguay, 5/6 families had CDKN2A mutations.19 
Phenotypic and genetic characterization of individuals at high 
risk for melanoma from Latin America may improve their 
management and implement genetic counseling in these coun-
tries. We present the molecular characterization of CDKN2A 
and MC1R genes in the largest set of patients at high risk for 
melanoma from distinct Latin American countries (Argentina, 
Brazil, Chile, Mexico, and Uruguay), and we compare the data 
with two sets of Spanish patients at high risk for melanoma to 
establish bases for genetic counseling in Latin America.
MATeRIALs AND MeTHODs
The multicenter cross-sectional study included 1,090 patients 
at high risk for melanoma: 758 patients with familial mela-
noma (FM) and 332 patients with SMP from Latin American 
countries and Spain. Because Latin America is a region with a 
low incidence of melanoma (GLOBOCAN 2012, World Health 
Organization; http://globocan.iarc.fr), the inclusion criteria fol-
lowed the rule of two.
Overall, 186 Latin American melanoma patients were 
recruited from Argentina (n = 10), Chile (n = 28), Mexico (n 
= 6), Uruguay (n = 25), and Brazil (n = 117), which included 
two sets of patients: Porto Alegre (Southern Brazil) (n = 58) 
and São Paulo (southeast region) (n = 59). The contribution of 
each country to the study resulted in a broad representation of 
a number of Latin American countries. A set of 904 Spanish 
patients with melanoma from Barcelona (n = 706) and Valencia 
(n = 198) also were included using the same selection criteria.
The number of primary melanomas, age at diagnosis, number 
of melanoma cases in the family, ancestral origin, and pheno-
typic data (hair and eye color, skin phototype, and nevi count) 
were recorded by dermatologists for most of the patients. 
Although the number of missing values was higher in the set of 
Spanish patients than in the Latin American patients, this did 
not introduce a bias, and the information recruited was infor-
mative for the whole cohort: Spanish patients were recruited 
consecutively, and missing data were distributed randomly; two 
different cohorts from Spain where used to minimize the bias 
due to the data collection procedure; and the variable with the 
greatest amount of missing data had information from at least 
600 Spanish patients. Partial genetic information of the patients 
with melanoma from Spain and Brazil, and a subset of pedi-
grees from Uruguay, has been previously reported.16–21
The study was approved by the ethical committee of the 
Hospital Clinic of Barcelona. The patients gave their written, 
informed consent.
CDKN2A and MC1R molecular screening
Molecular characterization of CDKN2A was performed in all 
patients. CDKN2A was sequenced in all patients, as previously 
described.16,18,20,21 MC1R was sequenced as described elsew-
ere.22,23 The MC1R genotype was available from all patients from 
Argentina and Chile, 57% (33/58) patients from Porto Alegre, 
Brazil, 92% (54/59) patients from São Paulo, Brazil, 96% (24/25) 
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patients from Uruguay, 59% (419/706) patients from Barcelona, 
Spain, and 94% (186/198) patients from Valencia, Spain. MC1R 
genotype data were not available for patients from Mexico.
statistical analyses
For the statistical analyses, the most common MC1R variants 
were classified as r variants (not associated with red hair color: 
p.V60L, p.V92M, p.R163Q) or R variants (associated with red 
hair color: p.D84E, p.R142H, p.R151C, p.I155T, p.R160W, 
p.D294H).10
SPSS software version 17.0 (IBM, Chicago, IL) was used. 
Two-sided Pearson χ2 or Fisher exact tests were used for cat-
egorical variables, as applicable. Student’s t-test was used for 
quantitative variables. Adjusted P values were calculated using 
the Bonferroni correction. The test was considered significant if 
the P value or adjusted P value (as applicable) was <0.05.
ResULTs
The study included a set of 1,090 patients with melanoma from 
distinct Latin American countries and Spain. Latin America 
and Spain had similar frequencies of FM cases (67.7 and 
69.9%, respectively) and SMP (32.3 and 30.1%, respectively; 
P = 0.600), and there were no gender differences (40.3% male 
and  58.7% female vs. 41.5% male and 58.5% female, respec-
tively; P = 0.806). Since Latin America is a mixed population 
from European, Native, African and Asian origin as a result of 
the colonization process and migratory effects,24 we collected 
information regarding the patients’ ancestral origin. The four 
grandparents of more than 70% of Latin American patients 
were of European origin. Latin American and Spanish patients 
differed in pigmentation traits. Latin American patients had 
fairer hair color (adjusted P = 0.016) and skin phototype 
(adjusted P < 0.001) than Spanish patients. No differences were 
observed for nevi count or eye color (Table 1).
Considering all patients, CDKN2A mutation prevalence was 
19% in Latin America and 12% in Spain. CDKN2A mutation fre-
quency in SMP was similar in Latin America (10%) and Spain 
(8.5%) (P = 0.623). However, the prevalence of CDKN2A muta-
tions in Latin American melanoma-prone families was higher 
than in Spain (24 and 14%, respectively; P = 0.019). The fre-
quency of mutations varied among countries. Whereas southern 
Brazil had a low mutation prevalence, Chile and Uruguay showed 
a high prevalence of mutations in both SMP and FM (Table 2).
The CDKN2A mutations differed in each country (Table 3). 
Overall, 74% (23/31) of Latin American CDKN2A mutation 
carriers had a mutation also found in Spanish patients with 
melanoma. The most prevalent mutations in Latin America 
(c.-34G>T and p.G101W (c.301G>T)) were among the most 
recurrent mutations in Spain, which are p.G101W (33%), 
p.V59G (c.176T>G) (7%), c.-34G>T (6%), p.A36RfsX17 
(c.106delG) (6%), and p.E120fsX145 (c.358delG) (5%) (Table 
3). Mutation c.-34G>T was present in 90% of families from 
Chile, and families from São Paulo (Brazil) and Uruguay with 
CDKN2A mutations. Mutation p.G101W was present in fami-
lies from Argentina, São Paulo (Brazil), and Uruguay. The other 
mutations detected in Latin America were restricted to a few 
pedigrees.
CDKN2A mutations have been previously associated with 
a lower age at diagnosis, number of primary melanomas, and 
the number of cases in the family.6 The whole set of patients 
also showed these associations (Table 4). Latin American 
patients with melanoma carrying a CDKN2A mutation had an 
increased number of cases in the family and a lower age at diag-
nosis, but the number of personal primary melanomas did not 
reach significance.
We sequenced MC1R to assess the distribution of MC1R 
variants across countries (Table 5). We observed differences in 
the number and type of variants between Latin America and 
Spain. We detected MC1R variants in 80.5% of Latin American 
and 67.9% of Spanish patients (P = 0.003), with a similar R 
variant frequency (39.6 vs. 36.3%, respectively; P = 0.514) but 
a higher r variant prevalence in Latin America (40.9 vs. 31.6%, 
respectively; P = 0.033). We analyzed the frequencies of the 
most common R and r variants, comparing Latin America 
and Spain (Supplementary Table S1 online). When adjust-
ing using the Bonferroni correction, we found a significantly 
increased presence of p.R160W (17.4 vs. 7.5%; adjusted P 
< 0.005) and p.R163Q (14.1 vs. 5.2%; adjusted P < 0.005) in 
Latin America, but we should take into consideration that all 
patients carrying the p.R163Q variant in this study were from 
only three study sites: Brazil (São Paulo), Chile, or Uruguay. 
The p.D294H variant was more frequent in Spain (5.4 vs. 
13.3%; adjusted P = 0.045). The presence of MC1R variants and 
R variants correlated with phenotype (Supplementary Tables 
S2 and S3 online).
DIsCUssION
Latin America has a low incidence of melanoma (GLOBOCAN 
2012). The characterization of melanoma genes has allowed 
other areas with low to medium incidence of melanoma, such 
as Spain, to recommend genetic counseling for patients with 
melanoma.12,25 To date, only a few specialized centers in Latin 
America offer melanoma genetic counseling, and there is little 
knowledge of the implication of high-risk genes in melanoma 
susceptibility. This study presents the clinical and molecular 
characterization of CDKN2A and MC1R in the largest set of 
Latin American patients at high risk for melanoma.
CDKN2A mutation frequency in melanoma-prone fami-
lies was higher in Latin America than Spain, using the same 
selection criteria. By contrast, both areas had similar SMP 
CDKN2A mutation prevalence, consistent with that reported 
in other studies (8.2–9%).25,26 The age at diagnosis and num-
ber of primary melanomas were associated with the presence 
of mutations in CDKN2A, as previously reported.6 Otherwise, 
we did not find associations between CDKN2A mutation 
and nevi count, suggesting that other genes could play a role 
in nevogenesis.27,28 Most CDKN2A mutations identified had 
been previously detected in European or North American 
patients with melanoma. The most prevalent mutation in 
Latin America was c.-34G>T. This mutation occurs at a high 
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frequency among unrelated families from Chile, suggesting a 
possible founder effect. In one family from Chile we detected 
p.R144C (c.430C>T), previously detected at the germline level 
in a patient with pancreatic cancer.29 Mutation p.G101W is also 
frequent in Latin America, as in Mediterranean countries (Italy, 
France, and Spain)7 where haplotype analysis showed a founder 
effect.30 We identified four other mutations in Brazil: p.P48T 
(c.142C>A), previously reported in an Italian population with 
FM,31 was found in four families, one of them of Italian ances-
try, suggesting a possible founder effect32; IVS2-105A>G and 
p.M53I (c.159G>C), previously reported in melanoma-prone 
families from the United Kingdom, Australia, and the United 
States7; and mutation p.V43L (c.127G>C), affecting p14ARF, 
which has not previously been reported. In Uruguay we detected 
p.E88X (c.262G>T) in two families, which also was detected in 
two Spanish pedigrees. In Mexico we identified a mutation in 
the two probands of one family—p.I49T (c.146T>C)—which 
was previously reported in a case of FM by Hussussian et al.33 
and did not segregate with melanoma in that case. However, 
functional analysis showed impairment for this variant.34
We detected differences in MC1R variant distribution in our 
set of patients. Latin American patients with melanoma carry 
more MC1R variants. These genetic results correlate with the 
phenotypic data, where Latin American patients with mela-
noma have fairer skin and hair color. The prevalence of MC1R 
variants varies between populations.35 In this study, specific 
variant frequencies differed between Latin American and 
Spanish patients with melanoma. Latin American patients 
with melanoma had an increased presence of p.R160W and 
p.R163Q. However, controls would be needed to assess the 
melanoma risk associated with carrying these variants in Latin 
America. p.R160W is associated with an increased risk for 
melanoma and red hair color.10 By contrast, p.R163Q, which is 
not associated with pigmentation or tanning response, favors 
the development of chronic sun exposure melanomas in the 
Mediterranean population22 and increases the risk for mela-
noma in areas with high ultraviolet radiation.36 These reports 
suggest that a possible interaction between p.R163Q and a 
high ultraviolet radiation dose could favor melanoma develop-
ment. Most Latin American countries receive a huge amount 
of ultraviolet radiation compared with northern latitudes; this 
could explain the increased frequency of SMP and FM with the 
p.R163Q variant in Latin America, although its frequency in a 
control Latin American population is unknown.
To date, genetic testing in patients at high risk for melanoma 
is restricted to CDKN2A and CDK4. More studies of patients 
wild type for these genes should be conducted to assess the role 
of other melanoma-susceptibility genes such as MITF, BAP1, 
TERT, POT1, ACD, and TERF2IF8 for their possible incor-
poration in melanoma genetic counseling. In this study we 
demonstrated that CDKN2A germline mutation frequency in 
melanoma-prone families with at least two melanoma cases is 
greater in Latin America than Spain (23.9 vs. 14.1%, respec-
tively). Inclusion criteria for genetic testing of melanoma 
in Spain follow the rule of two.12 Based on the results of this 
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study, the inclusion criteria for genetic counseling for patients 
with melanoma in Latin America should also follow this rule 
because it allows the detection of CDKN2A mutations in a sig-
nificant number of patients, except for southern Brazil, where 
the rule of three should be used. Genetic testing allows us to 
identify mutation carriers in families with a high risk of devel-
oping the disease. Carriers can be included in specific follow-up 
programs that allow the detection of melanomas at early stages, 
which improves the disease prognosis.3,37,38 Digital follow-up 
with specific dermatologic techniques, including total-body 
photography and digital dermoscopy, allow early detection of 
melanomas with a low rate of excision.38 Early melanomas in 
patients carrying MC1R variants may be difficult to diagnose 
definitively using dermoscopy, and an integrated approach 
including clinical history and dermoscopic data should be used 
when evaluating them.39 Thus, MC1R sequencing could also 
help to choose the best screening methods. The experience of 
genetic counseling in Spain over 10 years shows that melano-
mas can be diagnosed at any time, so the follow-up of individu-
als at high risk for melanoma should be maintained over time.12
In conclusion, Latin American patients with melanoma and 
at high risk for melanoma had fair skin and European ori-
gin. The mutations found also had been detected in Spanish, 
European, or North American populations, suggesting that 
they could have a single origin and that there could be a founder 
effect. Finally, inclusion criteria for genetic counseling in Latin 
American patients with melanoma should follow the rule of 
two: two primary melanomas in an individual or families with 
at least one invasive melanoma and one or more other diagno-
ses of melanoma or pancreatic cancer in first- or second-degree 
relatives.
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